BriaCell Therapeutics的空头股数在7月份下降了18.4%，机构投资者增加了股份，HC Wainwright维持“买入”评级。 BriaCell Therapeutics' short interest declined 18.4% in July, with Institutional investors increasing stakes, and HC Wainwright maintaining a "buy" rating.
BriaCell Therapeutics在晚期乳腺癌的3期试验中，7月份的空头股数下降了18.4%，从569,400股降至464,400股。 BriaCell Therapeutics, in Phase 3 trials for advanced breast cancer, saw a 18.4% decline in short interest in July, dropping from 569,400 to 464,400 shares. 加拿大国家银行FI、Onyx桥梁财富集团LLC和K.J等机构投资者。 Institutional investors like National Bank of Canada FI, Onyx Bridge Wealth Group LLC, and K.J. 哈里森与合作伙伴公司在第四季度增加了股份. Harrison & Partners Inc increased their stakes during Q4. HC Wainwright保持“买”评级和18美元的价格目标。 HC Wainwright maintains a "buy" rating and an $18.00 price target. 在第二季度,BCTX报告了0.11美元的每股收益,超过分析师估计的0.66美元. BCTX reported $0.11 EPS in Q2, exceeding analyst estimates by $0.66.